Cassie Kline

Scientific Committee
Executive Board

Philadelphia, PA USA

Children’s Hospital of Philadelphia



Director of Clinical Research in the Department of Neuro-Oncology at the Children's Hospital of Philadelphia

Children's Hospital of Philadelphia

Pediatric Neuro-Oncology, Clinical research, Early phase clinical trials in neuro-oncology, Developmental therapeutics


Children’s Hospital of Philadelphia

Philadelphia, PA, USA



Asset 26.png



Investigating Disease Mechanism In Adamantinomatous Craniopharyngioma Using New Cell Line Models

Adamantiomatious craniopharyngioma (ACP) is an intracranial tumor with no currently available targeted drug therapeutics. Using cell lines provided by the Children’s Brain Tumor Network, researchers will develop new models for use in identifying therapeutic opportunities for this disease.



Todd Hankinson

Children's Hospital of Colorado
Aurora, CO
Asset 2.png



Precision Imaging of Pediatric High-grade Gliomas with Quantitative Diffusion Weighted Imaging and Texture Analysis to Identify Imaging Biomarkers That Predict Tumor Genetics and Patient Outcomes

The recently characterized molecular marker, histone H3 K27M, could prove important to the treatment of pediatric gliomas. Researchers will interrogate data from the Pediatric Brain Tumor Atlas in order to better understand this new class of malignant gliomas.


Marian Aboian_008.jpg

Mariam Aboian

Yale School of Medicine
New Haven, CT, USA
Default project image



Diversity, Equity, and Inclusion: Translation of Informed Consent Forms

In November 2020, the FDA released guidance to help promote clinical trial enrollment practices that could lead to clinical trials that better reflect diverse populations who may benefit from treatments, medical devices, or drugs that are being investigated. Despite previous efforts, there remain gaps in inclusion of under-represented populations in many clinical trials. One of the barriers to being inclusive among all groups are the languages that are offered for informed consent practices. Currently, the Children’s Hospital of Philadelphia and collaborating institutions typically offer multilingual staff and informed consents in limited languages. But, the options available at each site vary and can be costly and burdensome at the level of each individual institution/clinical research team. Our goal is to remove this potential barrier by providing consortium level informed consents and study documents in multiple languages to ensure enrollment and recruitment of under-represented minorities (URM) in languages understood by a diverse population of patients and families. By providing these necessary resources, non-English speaking patients and families will be afforded the same opportunity to understand and participate in clinical trial enrollments as English-speaking patients and families.

All Brain Tumor Types


Cassie Kline

Children’s Hospital of Philadelphia
Philadelphia, PA, USA